The transdermal drug delivery system (TDDS) has some advantages as an alternative dosage form (i) avoiding firstpass metabolism, (ii) easy discontinuation of administration, and (iii) reduced side effects; however, the stratum corneum, which is the outermost layer of skin, provides a primary barrier to transdermal drug delivery.
tagonist analgesic, is used clinically for the relief of cancerrelated or postoperative pain, and PTZ shows an analgesic effect, a third as strong as morphine. As PTZ has a short halflife of 2 to 3 h 2) and undergoes extensive first-pass metabolism in the liver, conventional therapy with tablets or injection may result in unstable plasma concentration of the drug, which results in the induction of unexpected side effects. Long-term delivery of PTZ is thus needed at a controlled rate in the body for chronic pain management.
3) Mandal et al. have reported the percutaneous absorption of PTZ together with isopropyl myristate (IPM) as an enhancer, 4, 5) however, the enhanced skin permeation of PTZ is considered limited when IPM is used alone, and increased concentration of the enhancer would cause skin irritation. 6) It is well known that the combination of various enhancers improved the percutaneous absorption of drugs much greater than either enhancer alone. 7, 8) Regarding opioid analgesics, Morimoto et al. have reported that the percutaneous absorption of morphine hydrochloride was improved with a combination of l-menthol and ethanol. The cumulative amount of morphine permeated through hairless rat skin over 10 h was 5-fold times higher than the sum of those with 40% ethanol alone and l-menthol alone. 9) In the present study, therefore, we tried to improve the percutaneous absorption of PTZ using a combination of various enhancers. The skin permeation of PTZ through hairless mouse skin as a model membrane was determined using Franz diffusion cells and to select an appropriate enhancer for developing a new transdermal system. The flux, lag time and cumulative amount of permeated PTZ were measured as indicators of skin permeation improvement. Moreover, the effects of the structure of enhancers and hydrophiliclipophilic balance (HLB) on permeation rates of PTZ were discussed.
MATERIALS AND METHODS
Materials PTZ was purchased from Kobayashi Kako Co., Ltd. (Fukui, Japan). IPM, citric acid, urea, and 1-octadecanol were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). N-Methyl-2-pyrrolidone (Pharmasolve ® , Japanese Pharmaceutical Excipient grade) was a gift from ISP Japan (Tokyo, Japan). Glyceryl monocaprylate (GEFA-C 8 , Sunsoft ® 700P-2), glyceryl monocaprate (GEFA-C 10 , Sunsoft ® 760), glyceryl monolaurate (GEFA-C 12 , Sunsoft ® 750), gylceryl monostearete (GEFA-C 18 , Sunsoft ® 8000V) and glyceryl dicaprylate (GEFA-DiC 8 , Sunsoft ® GDC-S) were a gift from Taiyo Kagaku Co., Ltd. (Mie, Japan). Glyceryl tricaprylate (GEFA-TriC8, Panacate ® 800) and polyoxyethylene laurylether (NONION K-204) were a gift from NOF Corporation (Tokyo, Japan). Glyceryl monoethylate (GEFA-C 2 ), glyceryl monobutylate (GEFA-C 4 ) and glyceryl monocaproate (GEFA-C 6 ) were synthesized in our laboratory according to previous reports. [10] [11] [12] [13] [14] All other solvents and reagents were commercial products of analytical grade and were used without further purification.
Skin Permeation Studies The full-thickness dorsal skin of male hairless mice (5-10 weeks), sacrificed by ether, was excised, and adherent fat and other visceral debris were removed from the undersurface. In vitro permeation studies were carried out with Franz diffusion cells (Vertical diffusion cell TM , Hanson Research Corporation, CA, U.S.A.) at 32°C. The effective area of diffusion was 1.77 cm 2 , and the receiver cell volume was about 7 ml. The donor cell was filled with 200 ml of IPM solution containing 1% PTZ in the presence or absence of 10% enhancers. The receiver cell was filled with PBS (pH 7.4) and stirred at 650 rpm with a magnetic stirrer. April 16, 2007 The amount of permeated PTZ was quantitated by collecting 0.5 ml samples at designated time intervals. The volume of receptor fluid withdrawn was replaced with PBS. The concentration of PTZ in the sample was analyzed by HPLC, as described in the next paragraph.
Effect of Permeation Enhancers on the in Vitro
Analytical Method The HPLC system was constructed with a Model PU-2080 plus intelligent HPLC pump, a Model UV-2075 intelligent UV/VIS detector, and a Model AS-2055 plus intelligent sampler (Jasco Co., Tokyo, Japan). The analytical column, CAPCELL PAK C18, type MG (150 mmϫ 4.6 mm i.d., particle size 5 mm, Shiseido Co., Ltd., Tokyo, Japan) was used at room temperature. The mobile phase consisted of 0.05 M phosphoric acid and acetonitrile (77 : 23, v/v) at a flow rate of 1.0 ml/min. The column elute was monitored with ultraviolet wavelengths of 278 nm.
Data Analysis The cumulative amount of PTZ permeating across the skin was plotted against time. The steady state flux was calculated from the slope of the linear region of the above plot. The lag time was calculated by extrapolating the linear region of the curve to the X-axis.
RESULTS AND DISCUSSION

Screening Test for Effective Enhancers
First, we examined the enhancing effect of the skin permeation of PTZ with the combination of IPM and various enhancers. Table 1 shows permeation parameters of PTZ with various enhancers from the IPM solution system. All enhancers such as IPM, 5) carboxylic acids, 15) non-ionic surfactants, [16] [17] [18] l-menthol, 19) alcohols, glycol [20] [21] [22] and urea 23) were reported for their enhancing effects on the percutaneous absorption of various drugs. Of all enhancers used in this screening, the IPM solvent system containing GEFA-C 8 , which is a kind of glycerol ester of fatty acids (GEFAs), markedly enhanced PTZ permeation through the skin. The flux of PTZ combined with both GEFA-C 8 and IPM was ca. 4 times higher compared with IPM alone. It was also reported that the enhancement function of GEFA-C 8 in skin permeation contributed to the increased fluidity of sebaceous lipids and skin-moisturizing capacity. 24) In contrast, no significant enhancing effects were observed with other enhancers. It was considered that solubility made a relatively small contribution to the skin permeation of PTZ, because the PTZ concentration of donor cells was 1% of all IPM solution systems. Although IPM has been widely used as a safe permeation enhancer, its action mechanism has not been clarified in detail. Sato et al. suggested that IPM mainly affects the stratum corneum, and increases drug diffusivity in the stratum corneum and/or partition coefficient between the stratum corneum and vehicle of both the drug and solvent. 25) From the present screening test, the enhancing effect on the percutaneous absorption of PTZ from IPM solution system was improved with GEFA-C 8 .
Effect of GEFAs on Components in the Stratum corneum GEFA-C 8 is a GEFA derivative and thus there are different lengths and substitution degrees of alkyl chains. Some GEFA derivatives were reported as enhancers of the percutaneous absorption of drugs. 26, 27) Figure 1 shows the effect of the substitution degree of the caprylic chain in GEFA-C 8 on the skin permeation of PTZ. GEFA-DiC 8 and GEFATriC 8 did not have an enhancing effect on the skin permeation of PTZ. The rate and cumulative amount of permeated PTZ were similar to those in IPM alone without an enhancer. As a result, monosubstitution of the caprylate group in glyceryl caprylate, GEFA-C 8 , was efficient for the skin permeation of PTZ. Figure 2 shows that the effect of fatty chain length (C 2 -C 18 ) was derived from monoglyceride in the skin permeation of PTZ. Increasing the alkyl chain of GEFAs from GEFA-C 2 to GEFA-C 6 resulted in increasing the flux of PTZ. Although GEFA-C 6 showed the greatest enhancing effect among the GEFAs used, further increase in the alkyl chain of GEFAs from GEFA-C 6 caused a reduction in the PTZ flux. Okumura et al. investigated the skin permeation of papaverine hydrochloride promoted by GEFAs. The flux of papaverine hydrochloride was increased by increasing the alkyl chain of GEFAs from glyceryl monovalerate (side chain: C 5 to C 12 ).
In that report, GEFA-C 8 showed the maximum enhancing effect. The further increased the alkyl chain of GEFAs, the less reduction in the flux of papaverine. The amounts of various GEFAs had permeated through skin and were present in the skin at the end of 24 h permeation studies. There was a good linear relationship between the flux of the drug and the amount of GEFAs in skin (rϭ0.86). Short-chain GEFAs permeated through the skin, so that the amount of GEFA remaining in the skin was less than that of medium-chain GEFAs. They concluded that the enhancing effect of shortchain GEFAs was decreased. 28) Although water was used as the solvent in that report, we used the IPM solution system for the solvent. The permeability of PTZ peaked when GEFA-C 6 was used. The enhancing effect on the skin permeation of the drug peaked in GEFA of some carbon number, and was not related to the type of solvent. This indicated that the alkyl chain of GEFA had a suitable value from the drug. This result suggests that the carbon number of GEFAs is an important factor for the skin permeation promotion of PTZ.
Relationship between the HLB of GEFAs and the Flux of PTZ We evaluated the relationship between the enhancing effect on the flux of PTZ and the HLB values of GEFAs. The estimated HLB cal of GEFAs and the flux of PTZ are shown in Table 2 . The HLB cal value was determined by Griffin's equation as follows.
29) (1) where M H is the molecular weight of the hydrophobic moiety of the surfactant, and M W is the molecular weight of the surfactant. The HLB cal of GEFAs from side-chain C 18 to C 2 was calculated from 4.1 to 11.6. The highest flux of PTZ was indicated when the HLB cal value of GEFAs was about 8. It was speculated that the partition of PTZ from IPM as a solvent to the stratum coreneum would decrease, because long-chain GEFAs are low HLB cal values resulting in high lipophilicity. Moreover, it was considered that short-chain GEFAs do not affect the stratum corneum or remain in the skin tissue owing to permeation of the enhancer as mentioned above, because of their hydrophilic property.
Myoung and Choi studied the effect of various vehicles on the skin permeability of isosorbide dinitrate (ISDN). They revealed that the correlation between the HLB of vehicles and the flux of ISDN was not a linear relationship, but fitted to the second order polynomial. The maximum flux of ISDN was indicated when the HLB value of vehicles was about 7.
30) Park et al. also investigated the influence of polyoxyethoxylated non-ionic surfactants on the transport of ibuprofen across the rat skin. They also reported the HLB values of 7-9 of polyoxyethoxylated non-ionic surfactants were effective promoters of ibuprofen flux 31) ; therefore, our present result was consistent with previous findings. There may be an optimal HLB cal value in the promoting effect of GEFAs on the skin permeation of PTZ. We revealed that an HLB of GEFAs of about 8 seemed optimum for the enhancing effect on the percutaneous absorption of PTZ.
In conclusion, we demonstrated that the flux of PTZ was markedly enhanced by the combination of GEFAs and IPM. GEFA-C 6 indicated the greatest enhancing effect on the percutaneous absorption of PTZ among the GEFA enhancers examined. GEFA-C 8 showed a favorable ability to enhance the skin permeation of PTZ, indicating that this compound could be a possible candidate for a chemical percutaneous enhancer, because GEFA-C 8 has little smell and is a relatively safe ingredient (ex. Sunsoft 700P-2, as a food additive). 32) In contrast, GEFA-C 6 may not be suitable in formulations as it has a noxious smell and is unavailable commercially. In addition, these findings provide valuable information on the development of TDDS for PTZ. Vol. 30, No. 7 4 9.6 37.5Ϯ6.4 GEFA-C 6 8.2 158.2Ϯ12.5 GEFA-C 8 7.2 58.0Ϯ11.4 GEFA-C 10 6.5 52.6Ϯ3.3 GEFA-C 12 5.3 27.2Ϯ6.8 GEFA-C 18 4.1 9.7Ϯ3.9
HLB cal value was calculated from Griffin's Equation (Eq. 1). 29) Each value represents the meanϮS.D. (nϭ4).
